Medicomp gets US nod for ambulatory heart monitor:
This article was originally published in Clinica
United Therapeutics subsidiary Medicomp has received US FDA approval to market what it claims is the first ambulatory heart monitor to detect the p-wave, a diminutive but critical portion of an ECG that represents atrial activity. The CardioPAL SAVI monitor uses artificial intelligence to continually assess the heart, capturing ECG data from symptomatic patients while automatically recording asymptomatic ECG irregularities based on unusual rates, rhythms, or morphologies (waveform shapes). In addition, the system uses the Diogenes SV algorithm to perform real-time supraventricular analysis, said Melbourne, Florida-based Medicomp.